Abstract
More help could be on the way for the battle against renal cell carcinoma (RCC). Three new therapies showed promise in recent reports from the American Society of Clinical Oncology annual meeting. The benefits ranged from modest in a specific group of patients to potentially dramatic, which led the investigator to proclaim that a new standard of care has emerged.